BioSpace News Archive

Elgan Pharma announced that it has been awarded by the European Innovation Council a grant of €2.36 million in a highly competitive selection process.

Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody -associated vasculitis.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces new positive clinical data from the Company’s ongoing Phase I/II BEXMAB study.

Catalyst Pharmaceuticals, Inc., announced the completion of its acquisition from Santhera Pharmaceuticals Holdings of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy.

Teleflex Incorporated today announced the completion of patient enrollment in the prospective multicenter Ringer TM PTCA study.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a Clinical Trial Application to initiate a Phase 1/2 clinical trial of OTOF-GT in Europe.

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds of $60 million.

SCG Cell Therapy Pte Ltd, a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, has celebrated the official opening of its Cell Therapy cGMP Manufacturing Facility and R&D Centre at its headquarters in Singapore.

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2, 2023.

Onkos Surgical announced its launch of the JTS Extendible Prosthesis, a novel growing implant designed for pediatric patients with bone cancer, and unveiled its new, state-of-the-art manufacturing and R&D innovation center at its Parsippany, NJ headquarters to support the integration and growth of the technology.